Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objective: In a number of controlled clinical trials and naturalistic studies, aripiprazole once monthly (AOM) has been found to be effective and safe as acute and maintenance treatment options for schizophrenia. However, such clinical data have been presented in selected patient population (i.e., antipsychotic monotherapy, etc.), in particular, clinical information on switching to AOM from antipsychotic polypharmacy and/or other long acting injectable antipsychotics (LAIs) has been scarce till today. Methods: The study period was from the first switching day to AOM up to 12 months in patients with antipsychotic polypharmacy (APpoly)/LAIs (baseline, month 3, month 6, and month 12). Available demographics and clinical information were retrieved from electronic medical records (EMRs). Available scores of Global Assessment of Functioning (GAF), Clinical Global Impression-Clinical Benefit (CGI-CB), CGI-severity, Visual Analog Scale on Satisfaction-Patient/Health Professional (VAS-P/HP), and the Positive and Negative Syndrome Scale-Insigh (PANSS-I) scores were also taken from EMR. Proportional change of functional impairment before and after AOM was also captured. Results: Data of 18 patients were available. Most commonly used combined APs before AOM were aripiprazole, blonanserin, quetiapine, and risperidone. At least 2 APs (n = 2.4) were combined before AOM. Scores of GAF (10.7% increase), CGI-CB (46.2% decrease), VAS-P (47.8% increase), VAS-HP (40.8% increase), and PANSS-I (27.9% increase) (all p = 0.001) were significantly improved from baseline to month 12, respectively. Approximately 59% of patients improved individual functioning with different level (i.e., employment, back to school, etc.) after AOM treatment at month 12. Conclusion: The present study have clearly shown the clinical benefit and utility of switching to AOM for treatment of patients with APpoly/LAIs in routine practice. Subsequent, adequately-powered, well-controlled clinical trials may be necessary to confirm our findings in near future.
Abstract
Objective: In a number of controlled clinical trials and naturalistic studies, aripiprazole once monthly (AOM) has been found to be effective and safe as acute and maintenance treatment options for schizophrenia. However, such clinical data have been presented in selected patient population (i.e., antipsychotic monotherapy, etc.), in particular, clinical information on switching to AOM from antipsychotic polypharmacy and/or other long acting injectable antipsychotics (LAIs) has been scarce till today. Methods: The study period was from the first switching day to AOM up to 12 months in patients with antipsychotic polypharmacy (APpoly)/LAIs (baseline, month 3, month 6, and month 12). Available demographics and clinical information were retrieved from electronic medical records (EMRs). Available scores of Global Assessment of Functioning (GAF), Clinical Global Impression-Clinical Benefit (CGI-CB), CGI-severity, Visual Analog Scale on Satisfaction-Patient/Health Professional (VAS-P/HP), and the Positive and Negative Syndrome Scale-Insigh (PANSS-I) scores were also taken from EMR. Proportional change of functional impairment before and after AOM was also captured. Results: Data of 18 patients were available. Most commonly used combined APs before AOM were aripiprazole, blonanserin, quetiapine, and risperidone. At least 2 APs (n = 2.4) were combined before AOM. Scores of GAF (10.7% increase), CGI-CB (46.2% decrease), VAS-P (47.8% increase), VAS-HP (40.8% increase), and PANSS-I (27.9% increase) (all p = 0.001) were significantly improved from baseline to month 12, respectively. Approximately 59% of patients improved individual functioning with different level (i.e., employment, back to school, etc.) after AOM treatment at month 12. Conclusion: The present study have clearly shown the clinical benefit and utility of switching to AOM for treatment of patients with APpoly/LAIs in routine practice. Subsequent, adequately-powered, well-controlled clinical trials may be necessary to confirm our findings in near future.
참고문헌 (42)
- Otsuka Pharmaceutical Co., Ltd, "The manual of Abilify Maintena Kit" (2013), Otsuka Pharmaceutical Co., Ltd
- Pae CU, "Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia : systematic review and indirect treatment comparison", Int Clin Psychopharmacol, 32, pp.235~248 (2017)
- Park MH, "Aripiprazole treatment for patients with schizophrenia : from acute treatment to maintenance treatment", Expert Rev Neurother, 11, pp.1541~1552 (2011)
- Fleischhacker WW, "Aripiprazole once-monthly for treatment of schizophrenia : double-blind, randomised, non-inferiority study", Br J Psychiatry, 205, pp.135~144 (2014)
- Kane JM, "Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia : a 52-week, multicenter, randomized, double-blind, placebo-controlled study", J Clin Psychiatry, 73, pp.617~624 (2012)
- Ishigooka J, "Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia : a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole", Schizophr Res, 161, pp.421~428 (2015)
- Potkin SG, "Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole", Curr Med Res Opin, 29, pp.1241~1251 (2013)
- Kane JM, "Aripiprazole once-monthly in the acute treatment of schizophrenia : findings from a 12-week, randomized, double-blind, placebo-controlled study", J Clin Psychiatry, 75, pp.1254~1260 (2014)
- Fleischhacker WW, "Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia", Int Clin Psychopharmacol, 28, pp.171~176 (2013)
- Kane JM, "Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia", J Med Econ, 16, pp.917~925 (2013)
- Cameron C, "Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia : an indirect comparison of two double-blind placebo-controlled studies", Curr Med Res Opin, 34, pp.725~733 (2018)
- Schöttle D, "Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole : a 6-month, real-life non-interventional study", BMC Psychiatry, 18, pp.365~ (2018)
- Yan T, "Medication adherence and discontinuation of aripiprazole once-monthly 400 mg(AOM 400)versus oral antipsychotics in patients with schizophrenia or bipolar I disorder : a real-world study using US claims data", Adv Ther, 35, pp.1612~1625 (2018)
- Wang SM, "Schizophrenia relapse and the clinical usefulness of oncemonthly aripiprazole depot injection", Neuropsychiatr Dis Treat, 10, pp.1605~1611 (2014)
- Juckel G, "Towards a framework for treatment effectiveness in schizophrenia", Neuropsychiatr Dis Treat, 10, pp.1867~1878 (2014)
- Bobes J, "Recovery from schizophrenia : results from a 1-year follow-up observational study of patients in symptomatic remission", Schizophr Res, 115, pp.58~66 (2009)
- Peters-Strickland T, "The effect of aripiprazole once-monthly on personal and social functioning : post hoc analyses of acute and long-term studies", Neuropsychiatr Dis Treat, 15, pp.1659~1669 (2019)
- Naber D, "Qualify : a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia", Schizophr Res, 168, pp.498~504 (2015)
- Naber D, "Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study", Schizophr Res, 192, pp.205~210 (2018)
- Mustafa S, "Real-life assessment of aripiprazole monthly(Abilify Maintena)in schizophrenia : a Canadian naturalistic non-interventional prospective cohort study", BMC Psychiatry, 19, pp.114~ (2019)
- Peters-Strickland T, "Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia : a 52-week open-label study", NPJ Schizophr, 1, pp.15039~ (2015)
- Schreiner A, "Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: a prospective, open-label, interventional study", Psychopharmacology(Berl), 234, pp.3~13 (2017)
- Fleischhacker WW, "Critical review of antipsychotic polypharmacy in the treatment of schizophrenia", Int J Neuropsychopharmacol, 17, pp.1083~1093 (2014)
- Nielsen J, "10-year trends in the treatment and outcomes of patients with first-episode schizophrenia", Acta Psychiatr Scand, 122, pp.356~366 (2010)
- Gilmer TP, "Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004", Psychiatr Serv, 58, pp.1007~1010 (2007)
- 배치운, "Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and", or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study, 2020, pp.18(1), 153~158[DOI]
- Köhler O, "Association between Global Assessment of Functioning scores and indicators of functioning, severity, and prognosis in first-time schizophrenia", Clin Epidemiol, 8, pp.323~332 (2016)
- Correll CU, "Quantifying clinical relevance in the treatment of schizophrenia", Clin Ther, 33, pp.B16~ (2011)
- Christensen AF, "Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study", Acta Psychiatr Scand, 113, pp.148~153 (2006)
- Suzuki T, "Relationships between global assessment of functioning and other rating scales in clinical trials for schizophrenia", Psychiatry Res, 227, pp.265~269 (2015)
- Samara MT, "Equipercentile linking of scales measuring functioning and symptoms : examining the GAF, SOFAS, CGI-S, and PANSS", Eur Neuropsychopharmacol, 24, pp.1767~1772 (2014)
- Chue P, "The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia", Curr Med Res Opin, 29, pp.227~239 (2013)
- Han C, "Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial-or non-responsive to current antidepressants : a multi-center, naturalistic study", J Psychiatr Res, 49, pp.75~82 (2014)
- Woo YS, "Observational study to evaluate the clinical benefit of lamotrigine add-on therapy in bipolar patients in a naturalistic treatment setting", Asia Pac Psychiatry, 6, pp.334~341 (2014)
- Guy W, "ECDEU assessment manual for psychopharmacology" (1976), U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs
- Konsztowicz S, "Dimensions of insight in schizophrenia : Exploratory factor analysis of items from multiple self-and interviewer-rated measures of insight", Schizophr Res, 199, pp.319~325 (2018)
- Siu CO, "Insight and subjective measures of quality of life in chronic schizophrenia", Schizophr Res Cogn, 2, pp.127~132 (2015)
- Chue P, "The relationship between patient satisfaction and treatment outcomes in schizophrenia", J Psychopharmacol, 20(6 Suppl), pp.38~56 (2006)
- Marinis TD, "Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia", Pharmacopsychiatry, 40, pp.257~263 (2007)
- Potkin SG, "Multidimensional assessment of functional outcomes in schizophrenia : results from qualify, a head-tohead trial of aripiprazole once-monthly and paliperidone palmitate", Int J Neuropsychopharmacol, 20, pp.40~49 (2017)
- Kane JM, "Patient-centered outcomes with aripiprazole once-monthly for maintenance treatment in patients with schizophrenia : results from two multicenter, randomized, double-blind studies", Clin Schizophr Relat Psychoses, 9, pp.79~87 (2015)
- Hiroyuki Kamei, "Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia", Clinical Psychopharmacology and Neuroscience, 18(1), pp.49~57 (2020), 대한정신약물학회[DOI]